{"title":"From Reference Values to Clinical Impact: Monocyte-to-HDL Ratio (MHR) and Its Association with Inflammation and Mortality","authors":"Ahmed Arabi , Alaa Abdelhamid , Dima Nasrallah , Yaman Al-Haneedi , Deemah Assami , Raneem Alsheikh , Susu M. Zughaier ∗","doi":"10.1016/j.waojou.2026.101318","DOIUrl":"10.1016/j.waojou.2026.101318","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101318"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-03-05DOI: 10.1016/j.waojou.2026.101291
Alanoud Aljohani, Mofareh Alzahrani, Eman AlIdrissi, Khalid Alshaigi, Hamza Alghamdi
{"title":"A Rare Case of NFKB1 Deficiency Presenting with Omenn-Like Phenotype in an Infant: Diagnostic and Clinical Challenges","authors":"Alanoud Aljohani, Mofareh Alzahrani, Eman AlIdrissi, Khalid Alshaigi, Hamza Alghamdi","doi":"10.1016/j.waojou.2026.101291","DOIUrl":"10.1016/j.waojou.2026.101291","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101291"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-03-05DOI: 10.1016/j.waojou.2026.101325
Nasrin Moazzen, Sepideh Bagheri, Tahereh Sadeghi, Mohammad Pordel Barabadi
{"title":"Investigation of pulmonary function in children with diabetes mellitus type 1: a cross-sectional study","authors":"Nasrin Moazzen, Sepideh Bagheri, Tahereh Sadeghi, Mohammad Pordel Barabadi","doi":"10.1016/j.waojou.2026.101325","DOIUrl":"10.1016/j.waojou.2026.101325","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101325"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147449007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-03-05DOI: 10.1016/j.waojou.2026.101322
Ibtisam Musameh , Sarah Nazzal , Seyedeh Saba Nabavi , Rawan Salameh , Asmaa Ezzeldin
{"title":"Clinical Pharmacists-Led Allergy Verification in the Emergency Department: A pilot Study Driving Quality Improvement at Hamad General Hospital (HGH)","authors":"Ibtisam Musameh , Sarah Nazzal , Seyedeh Saba Nabavi , Rawan Salameh , Asmaa Ezzeldin","doi":"10.1016/j.waojou.2026.101322","DOIUrl":"10.1016/j.waojou.2026.101322","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101322"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147449062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-14DOI: 10.1016/j.waojou.2025.101159
Giorgio Walter Canonica MD , Gianenrico Senna MD , Luisa Brussino MD , Maria Aliani MD , Elena Altieri MD , Pietro Bracciale MD , Maria Filomena Caiaffa MD , Paolo Cameli MD , Marco Caminati MD , Cristiano Caruso MD , Stefano Centanni MD , Fausto De Michele MD , Stefano Del Giacco MD , Fabiano Di Marco MD , Laura Malerba MD , Francesco Menzella MD , Paola Rogliani MD , Micaela Romagnoli MD , Pietro Schino MD , Jan Walter Schroeder MD , Girolamo Pelaia MD
Background
Clinical remission is an emerging treatment goal in severe eosinophilic asthma (SEA). While benralizumab, an anti-IL-5Rα monoclonal antibody, has demonstrated efficacy in SEA, its ability to induce clinical remission in real-life settings over extended follow-up remains underexplored.
Methods
This post hoc analysis of the multicenter, retrospective ANANKE study evaluated clinical remission over 24 months in 167 Italian patients with SEA treated with benralizumab. Remission was defined according to the Severe Asthma Network Italy (SANI) criteria. Complete clinical remission (cCR) required the absence of oral corticosteroid (OCS) use and the presence of 3 criteria: no symptoms, no exacerbations, and stable lung function. Partial clinical remission (pCR) required the absence of OCS use and 2 of the 3 criteria. Outcomes were assessed at 3, 12, and 24 months.
Results
The proportion of patients achieving clinical remission increased over time: 87.2% at 3 months (40.4% pCR, 46.8% cCR), 95.0% at 12 months (17.5% pCR, 77.5% cCR), and 96.1% at 24 months (23.5% pCR, 72.6% cCR). No baseline demographic or clinical characteristics were found to significantly predict remission status. Blood eosinophil counts declined from a mean of 476.7 to 5.2 cells/μL at 24 months.
Conclusion
In this real-world Italian cohort, benralizumab was associated with rapid and sustained clinical remission in patients with SEA over 24 months. The high remission rates observed early and maintained throughout treatment support the role of benralizumab as a disease-modifying therapy and reinforce clinical remission as a meaningful therapeutic goal in SEA.
{"title":"Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study","authors":"Giorgio Walter Canonica MD , Gianenrico Senna MD , Luisa Brussino MD , Maria Aliani MD , Elena Altieri MD , Pietro Bracciale MD , Maria Filomena Caiaffa MD , Paolo Cameli MD , Marco Caminati MD , Cristiano Caruso MD , Stefano Centanni MD , Fausto De Michele MD , Stefano Del Giacco MD , Fabiano Di Marco MD , Laura Malerba MD , Francesco Menzella MD , Paola Rogliani MD , Micaela Romagnoli MD , Pietro Schino MD , Jan Walter Schroeder MD , Girolamo Pelaia MD","doi":"10.1016/j.waojou.2025.101159","DOIUrl":"10.1016/j.waojou.2025.101159","url":null,"abstract":"<div><h3>Background</h3><div>Clinical remission is an emerging treatment goal in severe eosinophilic asthma (SEA). While benralizumab, an anti-IL-5Rα monoclonal antibody, has demonstrated efficacy in SEA, its ability to induce clinical remission in real-life settings over extended follow-up remains underexplored.</div></div><div><h3>Methods</h3><div>This post hoc analysis of the multicenter, retrospective ANANKE study evaluated clinical remission over 24 months in 167 Italian patients with SEA treated with benralizumab. Remission was defined according to the Severe Asthma Network Italy (SANI) criteria. Complete clinical remission (cCR) required the absence of oral corticosteroid (OCS) use and the presence of 3 criteria: no symptoms, no exacerbations, and stable lung function. Partial clinical remission (pCR) required the absence of OCS use and 2 of the 3 criteria. Outcomes were assessed at 3, 12, and 24 months.</div></div><div><h3>Results</h3><div>The proportion of patients achieving clinical remission increased over time: 87.2% at 3 months (40.4% pCR, 46.8% cCR), 95.0% at 12 months (17.5% pCR, 77.5% cCR), and 96.1% at 24 months (23.5% pCR, 72.6% cCR). No baseline demographic or clinical characteristics were found to significantly predict remission status. Blood eosinophil counts declined from a mean of 476.7 to 5.2 cells/μL at 24 months.</div></div><div><h3>Conclusion</h3><div>In this real-world Italian cohort, benralizumab was associated with rapid and sustained clinical remission in patients with SEA over 24 months. The high remission rates observed early and maintained throughout treatment support the role of benralizumab as a disease-modifying therapy and reinforce clinical remission as a meaningful therapeutic goal in SEA.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101159"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145957886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-03-05DOI: 10.1016/j.waojou.2026.101287
Farah Khalid Farooqui , Mohammed Khalid Shariff , Khalid Farooqui
{"title":"En Coupe de Sabre – an Unusual case of Linear Scleroderma in Elderly female","authors":"Farah Khalid Farooqui , Mohammed Khalid Shariff , Khalid Farooqui","doi":"10.1016/j.waojou.2026.101287","DOIUrl":"10.1016/j.waojou.2026.101287","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101287"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-03-05DOI: 10.1016/j.waojou.2026.101288
Afnan A. Almutairi , Rand K. Arnaout
{"title":"First Reported Case of Hereditary Angioedema Due to MYOF Gene Mutation in Saudi Arabia","authors":"Afnan A. Almutairi , Rand K. Arnaout","doi":"10.1016/j.waojou.2026.101288","DOIUrl":"10.1016/j.waojou.2026.101288","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101288"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-03-05DOI: 10.1016/j.waojou.2026.101267
Sherin Rahim Thalappil , Sara Saeed Ibrahim Mohamed , Mariam Al-Nesf , Ramzy Mohammed Ali
{"title":"Cyclosporine (CSA) as Add-On Therapy in Omalizumab (OMA)–Refractory Chronic Spontaneous Urticaria: A Retrospective Review from Hamad General Hospital, Qatar","authors":"Sherin Rahim Thalappil , Sara Saeed Ibrahim Mohamed , Mariam Al-Nesf , Ramzy Mohammed Ali","doi":"10.1016/j.waojou.2026.101267","DOIUrl":"10.1016/j.waojou.2026.101267","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101267"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号